17 Einträge gefunden

1. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial

   1. Reich, Kristian
   2. Thyssen, Jacob P
   3. Blauvelt, Andrew
   4. Eyerich, Kilian
   5. Soong, Weily
   6. Rice, Zakiya P
   7. Hong, H Chih-Ho

   2022 - Forschungsinformationssystem des UKE
2. Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial

   1. Blauvelt, Andrew
   2. Langley, Richard G
   3. Lacour, Jean-Philippe
   4. Toth, Darryl
   5. Laquer, Vivian
   6. Beissert, Stefan
   7. Wollenberg, Andreas

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
3. Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1)

   1. Blauvelt, Andrew
   2. Kimball, Alexa B
   3. Augustin, Matthias
   4. Okubo, Yukari
   5. Witte, Michael M
   6. Capriles, Claudia Rodriguez
   7. Sontag, Angelina

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
4. Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study

   1. Blauvelt, Andrew
   2. Armstrong, April W
   3. Langley, Richard G
   4. Gebauer, Kurt
   5. Thaçi, Diamant
   6. Bagel, Jerry
   7. Guenther, Lyn C

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
5. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial

   1. Reich, Kristian
   2. Papp, Kim A
   3. Blauvelt, Andrew
   4. Langley, Richard G
   5. Armstrong, April
   6. Warren, Richard B
   7. Gordon, Kenneth B

   2021 - Forschungsinformationssystem des UKE
6. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial

   1. Gordon, Kenneth B
   2. Foley, Peter
   3. Krueger, James G
   4. Pinter, Andreas
   5. Reich, Kristian
   6. Vender, Ronald
   7. Vanvoorden, Veerle

   2021 - Forschungsinformationssystem des UKE
7. Differential Changes in Inflammatory Mononuclear Phagocyte and T-Cell Profiles within Psoriatic Skin during Treatment with Guselkumab vs. Secukinumab

   1. Mehta, Heena
   2. Mashiko, Shunya
   3. Angsana, Julianty
   4. Rubio, Manuel
   5. Hsieh, Ya-Ching M
   6. Maari, Catherine
   7. Reich, Kristian

   2021 - Forschungsinformationssystem des UKE
8. Bimekizumab versus Adalimumab in Plaque Psoriasis

   1. Warren, Richard B
   2. Blauvelt, Andrew
   3. Bagel, Jerry
   4. Papp, Kim A
   5. Yamauchi, Paul
   6. Armstrong, April
   7. Langley, Richard G

   2021 - Forschungsinformationssystem des UKE
9. Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure

   1. Armstrong, April
   2. Paul, Carle
   3. Puig, Luis
   4. Boehncke, Wolf Henning
   5. Freeman, Michael
   6. Torii, Hideshi
   7. Papp, Kim

   2020 - Forschungsinformationssystem des UKE
10. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study

    1. Deleuran, Mette
    2. Thaçi, Diamant
    3. Beck, Lisa A
    4. de Bruin-Weller, Marjolein
    5. Blauvelt, Andrew
    6. Forman, Seth
    7. Bissonnette, Robert

    2020 - Forschungsinformationssystem des UKE
11. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial

    1. Reich, Kristian
    2. Armstrong, April W
    3. Langley, Richard G
    4. Flavin, Susan
    5. Randazzo, Bruce
    6. Li, Shu
    7. Hsu, Ming-Chun

    2019 - Forschungsinformationssystem des UKE
12. Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: Results Through 48 Weeks of a Phase 3, Multicenter, Randomized, Double-Blinded, Etanercept- and Placebo-Controlled Study (CIMPACT)

    1. Lebwohl, Mark
    2. Blauvelt, Andrew
    3. Paul, Carle
    4. Sofen, Howard
    5. Węgłowska, Jolanta
    6. Piguet, Vincent
    7. Burge, Daniel

    2018 - Forschungsinformationssystem des UKE
13. Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study

    1. Puig, Lluís
    2. Augustin, Matthias
    3. Blauvelt, Andrew
    4. Gottlieb, Alice B
    5. Vender, Ron
    6. Korman, Neil J
    7. Thaçi, Diamant

    2018 - Forschungsinformationssystem des UKE
14. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

    1. Gordon, Kenneth B
    2. Strober, Bruce
    3. Lebwohl, Mark
    4. Augustin, Matthias
    5. Blauvelt, Andrew
    6. Poulin, Yves
    7. Papp, Kim A

    2018 - Forschungsinformationssystem des UKE
15. Rapid Improvements in Health-related Quality of Life and Itch with Ixekizumab Treatment in Randomized Phase 3 Trials: Results from UNCOVER-2 and UNCOVER-3

    1. Leonardi, Craig L
    2. Blauvelt, Andrew
    3. Sofen, H L
    4. Gooderham, M
    5. Augustin, M
    6. Burge, R
    7. Zhu, B

    2017 - Forschungsinformationssystem des UKE
16. Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders. A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)

    1. Blauvelt, Andrew
    2. Papp, Kim A
    3. Griffiths, Christopher E M
    4. Puig, Luis
    5. Weisman, Jamie
    6. Dutronc, Yves
    7. Kerr, Lisa Farmer

    2017 - Forschungsinformationssystem des UKE
17. Continuous Dosing Versus Interrupted Therapy with Ixekizumab: An Integrated Analysis of Two Phase 3 Trials in Psoriasis

    1. Blauvelt, Andrew
    2. Papp, K A
    3. Sofen, H L
    4. Augustin, M
    5. Yosipovitch, Gil
    6. Katoh, N
    7. Mrowietz, U

    2017 - Forschungsinformationssystem des UKE